Literature DB >> 24195114

FDA permits marketing of first US test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24195114

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  12 in total

1.  Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

Authors:  Grant Theron; Rouxjeane Venter; Greg Calligaro; Liezel Smith; Jason Limberis; Richard Meldau; Duncan Chanda; Aliasgar Esmail; Jonny Peter; Keertan Dheda
Journal:  Clin Infect Dis       Date:  2016-02-16       Impact factor: 9.079

2.  Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States.

Authors:  Christopher K Lippincott; Melissa B Miller; Elena B Popowitch; Colleen F Hanrahan; Annelies Van Rie
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

3.  Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial.

Authors:  J Lucian Davis; L Masae Kawamura; Lelia H Chaisson; Jennifer Grinsdale; Jihane Benhammou; Christine Ho; Anna Babst; Houmpheng Banouvong; John Z Metcalfe; Mark Pandori; Philip C Hopewell; Adithya Cattamanchi
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

4.  Diagnosis of Concurrent Pulmonary Tuberculosis and Tuberculous Otitis Media Confirmed by Xpert MTB/RIF in the United States.

Authors:  Kathleen M Tompkins; Melissa A Reimers; Becky L White; Michael E Herce
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2016-05

5.  Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.

Authors:  Anne F Luetkemeyer; Cynthia Firnhaber; Michelle A Kendall; Xingye Wu; Gerald H Mazurek; Debra A Benator; Roberto Arduino; Michel Fernandez; Elizabeth Guy; Pamela Johnson; Beverly Metchock; Fred Sattler; Edward Telzak; Yun F Wang; Marc Weiner; Susan Swindells; Ian M Sanne; Diane V Havlir; Beatriz Grinsztejn; David Alland
Journal:  Clin Infect Dis       Date:  2016-02-02       Impact factor: 9.079

6.  Diagnosis of tuberculosis by using a nucleic acid amplification test in an urban population with high HIV prevalence in the United States.

Authors:  Miwako Kobayashi; Susan M Ray; John Hanfelt; Yun F Wang
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

7.  Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.

Authors:  James F Cowan; Aldine S Chandler; Elizabeth Kracen; David R Park; Carolyn K Wallis; Emelline Liu; Chao Song; David H Persing; Ferric C Fang
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

Review 8.  Rapid molecular assays for detection of tuberculosis.

Authors:  Rkia Eddabra; Hassan Ait Benhassou
Journal:  Pneumonia (Nathan)       Date:  2018-05-25

9.  Rapid molecular testing for TB to guide respiratory isolation in the U.S.: a cost-benefit analysis.

Authors:  Alexander J Millman; David W Dowdy; Cecily R Miller; Robert Brownell; John Z Metcalfe; Adithya Cattamanchi; J Lucian Davis
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

10.  Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments.

Authors:  Grant Theron; Jonny Peter; Greg Calligaro; Richard Meldau; Colleen Hanrahan; Hoosain Khalfey; Brian Matinyenya; Tapuwa Muchinga; Liezel Smith; Shaheen Pandie; Laura Lenders; Vinod Patel; Bongani M Mayosi; Keertan Dheda
Journal:  Sci Rep       Date:  2014-07-11       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.